CORT - William Guyer Expands Holdings With Corcept Therapeutics Stock Options | Benzinga
A noteworthy insider acquisition was disclosed on February 14, as Guyer, Chief Development Officer at Corcept Therapeutics (NASDAQ:CORT), reported the acquisition of stock options for 200,000 shares.
What Happened: Guyer, Chief Development Officer at Corcept Therapeutics, acquired stock options for 200,000 shares of CORT. This information was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday. The options allow Guyer to buy the company's stock at $23.01 per share.
Currently, Corcept Therapeutics shares are trading down 0.0%, priced at $23.05 during Wednesday's morning. This values Guyer's 200,000 shares at $7,999.
Delving into Corcept Therapeutics's Background
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Understanding the Numbers: Corcept Therapeutics's Finances
Revenue Growth: Over the 3 months period, Corcept Therapeutics showcased positive performance, achieving a revenue growth rate of 21.5% as of 30 September, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care ...